T. E. Rudd

CHICAGO – Pairing the immune checkpoint inhibitors nivolumab and ipilimumab delivered deep and durable responses in patients with advanced metastatic melanoma, producing a 2-year overall survival rate of 79% among 53 patients.

"These are remarkable data even for a trial of this size in metastatic melanoma," noted Dr. Mario Sznol, a professor of medical oncology at Yale University, New Haven, Conn.

In a video interview at the annual meeting of the American Society for Clinical Oncology, Dr. Sznol discusses the study results, and he outlines how combinations of new agents with older treatments such as interferon and interleukin-2 may be used in the future.

CHICAGO – Pairing the immune checkpoint inhibitors nivolumab and ipilimumab delivered deep and durable responses in patients with advanced metastatic melanoma, producing a 2-year overall survival rate of 79% among 53 patients.

"These are remarkable data even for a trial of this size in metastatic melanoma," noted Dr. Mario Sznol, a professor of medical oncology at Yale University, New Haven, Conn.

In a video interview at the annual meeting of the American Society for Clinical Oncology, Dr. Sznol discusses the study results, and he outlines how combinations of new agents with older treatments such as interferon and interleukin-2 may be used in the future.

CHICAGO – Pairing the immune checkpoint inhibitors nivolumab and ipilimumab delivered deep and durable responses in patients with advanced metastatic melanoma, producing a 2-year overall survival rate of 79% among 53 patients.

"These are remarkable data even for a trial of this size in metastatic melanoma," noted Dr. Mario Sznol, a professor of medical oncology at Yale University, New Haven, Conn.

In a video interview at the annual meeting of the American Society for Clinical Oncology, Dr. Sznol discusses the study results, and he outlines how combinations of new agents with older treatments such as interferon and interleukin-2 may be used in the future.